Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Potential Flu Drugs Target Immune Response, Not Virus

By Drug Discovery Trends Editor | July 22, 2014

Avian influenza A (H7N9). (Source: WHO Collaborating Centre for Reference and Research on Influenza/National Institute of Infectious Diseases, Japan)The seriousness of disease often results from the strength of immune response, rather than with the virus, itself. Turning down that response, rather than attacking the virus, might be a better way to reduce that severity, said Juliet Morrison of the University of Washington, Seattle. She and her collaborators have now taken the first step in doing just that for the H7N9 influenza, and their work has already led to identification of six potential therapeutics for this highly virulent strain. The research is published ahead of print in the Journal of Virology.
 
“We set out to characterize the response to the severe disease-causing H7N9 virus and compare it to responses elicited by other serious flu viruses in a mouse model of infection,” said Morrison. That work involved determining which genes are turned on by this infection.
 
“We have found that viruses that cause severe illness, like H7N9 and the infamous 1918 virus, trigger gene expression signatures that are different from the signatures seen in milder infections,” said coauthor and University of Washington colleague Michael Katze, in whose laboratory the work was performed. “Importantly, we can exploit these signatures for antiviral drug discovery,” he added.
 
The investigators then used a computational approach to identify potentially therapeutic drugs. They searched databases containing gene expression profiles of cultured human cells that had been treated with different drugs, in order to find those that were the reverse of expression profiles induced by the H7N9 flu virus, and noting the drugs that accomplished this, said Morrison. These drugs could potentially dampen the harmful host response, she said. 
 
“Six of these drugs are FDA approved and could potentially be repurposed as H7N9 influenza therapeutics,” said Morrison. “I believe that computational biology represents an exciting new way to study viruses and to discover drugs to fight them.”
 
And that, she said, is what drew her to join Katze’s laboratory.
 
The H7N9 avian influenza, which emerged in February, 2013, has caused those infected to become extremely ill, reminiscent of the 1918 influenza pandemic, the deadliest on record. The data suggests that such severe influenzas are associated with increased transcription of inflammatory cytokine genes, and reduced transcription of lipid metabolism and coagulation genes, according to the paper. Further study of these phenomena will lead to a better understanding of severe influenza, and could help investigators to identify potential therapeutics aimed at turning down the response.
 
Investigators from the Centers for Disease Control and Prevention, and the United States Department of Agriculture, took part in this research.
 
Date: July 21, 2014
Source: American Society for Microbiology

Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE